ARL4C and colorectal carcinoma: Intriguingly, a dose-dependent cell viability determination assay (Figure S2A) exhibited a negative correlation between ARL4C expression and oxaliplatin sensitivity in six CRC cell lines at 72 h after oxaliplatin treatment (Figure S2A).